Oruka Therapeutics Shares Climb 11% as Psoriasis Drug Fully Clears Skin in 61% of Patients in Mid-Stage Trial
Oruka Therapeutics Inc. shares rose 11.49% to $89.36 after reporting mid-stage trial results for its psoriasis drug ORKA-001. The highest dose achieved 61% complete skin clearance in patients, with 86% showing at least 90% improvement. The company aims for once-a-year dosing, pending further trials and regulatory discussions. Oruka's market value is now about $5.9 billion.
How this was made
The 30-second read
Why it matters
The article provides a fresh efficacy and safety snapshot at week 16, plus a concrete Phase 3 timeline and maintenance-study design, which can shift perceived probability of success and near-term biotech sentiment.
Market read
Traders get a same-day catalyst from newly reported Phase 2b PASI 100 efficacy at the highest dose, with a stated path to Phase 3 and maintenance testing.
What to watch
Placebo had zero PASI 100, but the key risk is whether complete clearance persists through the maintenance randomization and whether Phase 3 regulators accept the program design and endpoints.
Background
Oruka is developing ORKA-001, an IL-23 antibody, in a Phase 2b trial (EVERLAST-B) for moderate-to-severe plaque psoriasis, with a plan to test once-yearly dosing in the next phase.
Ticker impact
Oruka reported Phase 2b EVERLAST-B results for ORKA-001, with 61% achieving complete skin clearance at the 600 mg dose versus zero on placebo at week 16.
Likely upward bias as traders price in improved probability of Phase 3 success and a differentiated IL-23 profile, despite only 16-week data.
The article discloses statistically significant PASI 100 at the highest dose, dose-response efficacy, and a low safety signal through 16 weeks, which are direct drivers for biotech risk-reward repricing.
Market effects
Reinforces competitive pressure in IL-23 psoriasis biologics by highlighting higher complete-clearance rates with less frequent dosing as a potential differentiator.
Primarily US-listed biotech sentiment impact via Nasdaq-listed Oruka’s same-session move.
Could influence global psoriasis-treatment expectations around IL-23 class efficacy benchmarks, though data are still early (16-week).
Counterpoint
The maintenance and once-yearly dosing concept is unproven; traders may fade the move if longer-term durability or safety emerges in later cohorts.
Key entities
- companyOruka Therapeutics Inc.
Nasdaq-listed biotech whose shares rose after reporting Phase 2b week-16 results for ORKA-001 in plaque psoriasis.
- drug_candidateORKA-001
Experimental IL-23 antibody in EVERLAST-B, targeting complete skin clearance (PASI 100).
- clinical_trialEVERLAST-B (Phase 2b)
Randomized, double-blind, placebo-controlled study enrolling 187 patients across US, Canada, and Europe.
